Search results for "heart Failure"

showing 10 items of 863 documents

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Type 2 Myocardial Infarction: A Geriatric Population-based Model of Pathogenesis

2019

International audience; Distinction between type 2 myocardial infarction (T2MI), defined as an imbalance between oxygen supply and demand without atherothrombosis, and type 1 myocardial infarction (T1MI), due to plaque disruption, is often a clinical challenge in frail elderly patients. We aimed to identify the characteristics and underlying causes of T2MI using a comprehensive geriatric approach. From a multicentre population-based prospective study in coronary care units, we adjudicated 4572 consecutive patients hospitalized for an acute T1MI or T2MI, according to the 3rd universal definition and a prespecified geriatric model of T2MI pathogenesis. In total, 3710 (81%) had T1MI and 862 (1…

0301 basic medicineRiskmedicine.medical_specialtyrespiratory tract infectionPopulationOutcomesLower riskOrginal ArticlePathology and Forensic Medicinetype 2 myocardial infarctionPathogenesis03 medical and health sciences0302 clinical medicineInternal medicineMedicineDiseaseMyocardial infarctionMortalityProspective cohort studyeducationFeatureseducation.field_of_studybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyVaccinationRespiratory infectionaortic stenosisCell Biologymedicine.diseaseanemia3. Good healthStenosis030104 developmental biologyHeart failureCardiologyNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgerytachyarrhythmia pathophysiology
researchProduct

Heat Shock Protein 60 in Cardiovascular Physiology and Diseases.

2020

Heat shock protein 60 (HSP60) is a highly conserved protein abundantly expressed in both prokaryotic and eukaryotic cells. In mammals, HSP60 has been primarily considered to reside in the mitochondria, where HSP60 and HSP10 form a complex and facilitate mitochondrial protein folding. However, HSP60 is also observed in the cytoplasm, the plasma membrane, and the extracellular space. HSP60 regulates a broad spectrum of cellular events including protein trafficking, peptide hormone signaling, cell survival, cell proliferation, inflammation, and immunization. In the cardiovascular system, growing evidence indicates that HSP60 could not only play an important role under physiological conditions,…

0301 basic medicineanimal structuresMini Reviewheat shock proteinheart failureInflammationchemical and pharmacologic phenomenacardiomyocyteBiologyMitochondrionBiochemistry Genetics and Molecular Biology (miscellaneous)Biochemistrycomplex mixtures03 medical and health sciences0302 clinical medicineHeat shock proteinmedicineMolecular Bioscienceslcsh:QH301-705.5Molecular BiologyCell growthfungiCardiovascular physiologyCell biology030104 developmental biologylcsh:Biology (General)Cytoplasm030220 oncology & carcinogenesisHSP60medicine.symptomSignal transductionatherosclerosisHSP60Frontiers in molecular biosciences
researchProduct

Impact of Oxidative Stress on the Heart and Vasculature

2017

Abstract Vascular disease and heart failure impart an enormous burden in terms of global morbidity and mortality. Although there are many different causes of cardiac and vascular disease, most causes share an important pathological mechanism: oxidative stress. In the failing heart, oxidative stress occurs in the myocardium and correlates with left ventricular dysfunction. Reactive oxygen species (ROS) negatively affect myocardial calcium handling, cause arrhythmia, and contribute to cardiac remodeling by inducing hypertrophic signaling, apoptosis, and necrosis. Similarly, oxidative balance in the vasculature is tightly regulated by a wealth of pro- and antioxidant systems that orchestrate r…

0301 basic medicinechemistry.chemical_classificationReactive oxygen speciesNecrosisVascular diseasebusiness.industryAngiogenesisOxidative phosphorylation030204 cardiovascular system & hematologymedicine.diseasemedicine.disease_causeCell biology03 medical and health sciences030104 developmental biology0302 clinical medicinechemistryApoptosisHeart failureImmunologymedicinemedicine.symptomCardiology and Cardiovascular MedicinebusinessOxidative stressJournal of the American College of Cardiology
researchProduct

Do urocortins have a role in treating cardiovascular disease?

2018

Corticotropin-releasing factor (CRF) and the three homolog neuropeptides, urocortin (UCN) 1, 2 and 3, are the major neuroendocrine factors implicated in the response of the body to stress. Recent evidence suggests that UCNs have a significant role in the pathogenesis and management of cardiovascular disease, such as congestive heart failure, ischemic heart disease, and hypertension. These data led to the initiation of clinical trials testing a possible role of UCNs in the diagnosis and therapy of cardiovascular disease, with encouraging results. Here, we summarize the available literature concerning the role of UCNs in the cardiovascular system, focusing on the emerging data creating a pote…

0301 basic medicineendocrine systemCorticotropin-Releasing HormoneDiseaseBioinformaticsCardiovascular SystemPathogenesis03 medical and health sciences0302 clinical medicineDrug Discoveryotorhinolaryngologic diseasesMedicineAnimalsHumansUrocortinsPharmacologyUrocortinbusiness.industrymedicine.diseaseClinical trial030104 developmental biologyCardiovascular Diseases030220 oncology & carcinogenesisHeart failurebusinessIschemic heartUrocortinsDrug discovery today
researchProduct

MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure.

2016

Cardiac remodelling is a complex pathogenetic pathway involving genome expression, molecular, cellular, and interstitial changes that cause changes in size, shape and function of the heart after cardiac injury. Areas covered: We will review recent advances in understanding the role of several receptor-mediated signaling pathways and micro-RNAs, in addition to their potential as candidate target pathways in the pathogenesis of heart failure. The myocyte is the main target cell involved in the remodelling process via ischemia, cell necrosis and apoptosis (by means of various receptor pathways), and other mechanisms mediated by micro-RNAs. We will analyze the role of some receptor mediated sig…

0301 basic medicineheart failure target micro-RNA receptorSettore MED/09 - Medicina InternaClinical BiochemistryCellApoptosisBiology03 medical and health scienceschemistry.chemical_compoundGSK-3Drug DiscoverymicroRNAmedicineAnimalsHumansMyocytes CardiacAntagomirMolecular Targeted TherapyReceptorHeart FailurePharmacologyVentricular RemodelingReceptor-mediated endocytosisCell biologyMicroRNAs030104 developmental biologymedicine.anatomical_structurechemistryImmunologyMolecular MedicineSignal transductionSignal TransductionRelaxin receptor
researchProduct

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

2019

Visual Abstract

0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiac & Cardiovascular Systemsempagliflozinheart failure030204 cardiovascular system & hematologySGLT2i sodium-glucose co-transporter 2 inhibitorHF heart failurePRECLINICAL RESEARCH03 medical and health sciences0302 clinical medicineDM diabetes mellitusDiabetes mellitusInternal medicinemedicineEmpagliflozinMI-HF post-infarct heart failureGlycemicScience & TechnologyEjection fractionbusiness.industryNHE sodium-hydrogen exchangerANN artificial neural networkmedicine.diseaseHFrEF HF with reduced ejection fractionBlockadeXIAPmachine learning030104 developmental biologyMechanism of actionlcsh:RC666-701Heart failureCardiovascular System & CardiologyCardiologyRNAseq RNA sequencingempagtiflozinmedicine.symptomCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineJACC: Basic to Translational Science
researchProduct

Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort

2020

Abstract Background Beta-hemolytic streptococci (BHS) are an uncommon cause of infective endocarditis (IE). The aim of this study was to describe the clinical features and outcomes of patients with BHS IE in a large multinational cohort and compare them with patients with viridans streptococcal IE. Methods The International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) is a large multinational database that recruited patients with IE prospectively using a standardized data set. Sixty-four sites in 28 countries reported patients prospectively using a standard case report form developed by ICE collaborators. Results Among 1336 definite cases of streptococcal IE, 823 were ca…

0301 basic medicinemedicine.medical_specialty030106 microbiologycardiac devicesHospital mortalitymedicine.disease_cause03 medical and health sciencesbeta-hemolytic streptococciBacterial endocarditismedicineMajor ArticleEndocarditisGynecologyInternational Collaboration on Endocarditibusiness.industryStreptococcusinfective endocarditiscardiac devicemedicine.disease3. Good health030104 developmental biologyInfectious DiseasesBeta-hemolyticAcademicSubjects/MED00290congestive heart failure[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyOncologyInfective endocarditisCohortInternational Collaboration on EndocarditisBeta-hemolytic streptococcusbusiness
researchProduct

Galectin-3 in acute coronary syndrome

2017

Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This art…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeAcute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical BiochemistryPrognosiGalectinsGalectin 3Clinical BiochemistryMyocardial InfarctionDisease030204 cardiovascular system & hematologyAMI03 medical and health sciences0302 clinical medicineFibrosismedicineHumansGalectin-3Myocardial infarctionIntensive care medicineHeart FailureEvidence-Based Medicinebiologybusiness.industryGold standardGeneral MedicineBlood ProteinsBiomarkermedicine.diseaseAtherosclerosisPrognosisTroponin030104 developmental biologyGalectin-3Heart failureAtherosclerosibiology.proteinAcute coronary syndromebusinessBiomarkersHuman
researchProduct

Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure

2019

> You wouldn't wear just any pair of glasses—your prescription is tailored to your vision. This statement was made by President Obama in 2016 during the presentation and launch of the Precision Medicine Initiative. Whether we like it or not (and some politicians today seem rather indifferent), we are headed toward a new paradigm of precision medicine. This is a new era of medicine in which the right treatment is delivered at the right time to the right person. In the context of heart failure (HF)5 there is a long road ahead to fully realize the goals of precision medicine. HF is a complex syndrome with heterogeneous pathophysiology. Most medical treatments currently used in HF have been tes…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryContext (language use)030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumansIn patientPrecision MedicineMedical prescriptionIntensive care medicineHeart FailureEjection fractionbusiness.industryBiochemistry (medical)Precision medicinemedicine.disease030104 developmental biologyHeart failureBiomarker (medicine)NeprilysinbusinessBiomarkersClinical Chemistry
researchProduct